Actively Recruiting
Safety and Effectiveness Study of Onasemnogene Abeparvovec Intrathecal Injection for Spinal Muscular Atrophy Patients in Japan
Led by Novartis Pharmaceuticals · Updated on 2026-10-22
80
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of onasemnogene abeparvovec delivered by intrathecal injection in patients with spinal muscular atrophy SMA in Japan. This observational study collects real-world data without imposing specific treatment protocols or visit schedules, allowing patients to receive care according to approved guidelines. Patients treated with onasemnogene abeparvovec intrathecal injection are monitored in this study. Data is gathered through case registration forms filled out by investigators at each site. No experimental therapy schedules or additional procedures are required beyond routine clinical practice. Participants health is tracked for up to about four years and five months. Researchers assess serious adverse events, adverse drug reactions, and changes in motor function and developmental milestones using various standardized scales. Safety and effectiveness outcomes are regularly recorded to understand long-term patient experiences with the treatment.
CONDITIONS
Brief Title
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here